
    
      Subjects will receive one of two treatment regimens:

      Group A: intravenous drip of liposomal doxorubicin 36 mg/m2, d1、d15，1h； VCR 1.4mg/m2.d
      d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28
      ivdrip，once every 28days.

      Group B: intravenous drip of DNR45mg/m2，d d1～3，1h；VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX
      800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip，once every 28days.
      The primary endpoint is complete remission after the first course treatment of induced
      remission chemotherapy, to evaluated the ratio of CR patients after the first course of
      chemotherapy with PLD and DNR VDCLD regimens.The secondary endpoint is to evaluate the
      changes of myeloid leukemia stem cells in patients before and after induction of VDCLD with
      PLD and DNR respectively.
    
  